Streetbeat News

PBLA

Panbela Therapeutics Inc.

http://www.sunbiopharma.com/

CEO

Michael Cullen

Open

0.37

Mkt cap

1.8M

Volume

605

High

0.37

P/E Ratio

-0.01

52-wk high

1.11

Low

0.37

Div yield

N/A

52-wk low

0.30

Panbela Therapeutics has entered into agreements with certain stockholders for a $2 million private placement. This involves the exercise of existing warrants for 2,556,000 shares of common stock at $0.78 per share, in exchange for new warrants.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 2:30 pm

Panbela Therapeutics Inc (NASDAQ:PBLA) stock dropped 25% to $1.18 after a recent surge. The decline follows the FDA approval of eflornithine, a drug Panbela divested to US WorldMeds, for high-risk neuroblastoma patients. Despite the approval being a positive development, the stock has retreated from its recent highs. Panbela could earn $9.5 million based on milestones from US WorldMeds. The company sees the approval as a significant step for polyamine targeted therapy in cancer treatment.

Portfolio Pulse from Henry Khederian

December 20, 2023 | 6:37 pm

During Wednesday's intraday session, several healthcare stocks experienced significant movements. MSP Recovery (LIFW), Liquidia (LQDA), ENDRA Life Sciences (NDRA), Beyond Air (XAIR), Vicarious Surgical (RBOT), and Conduit Pharmaceuticals (CDT) saw their shares rise between 18.89% and 38.0%. Conversely, bluebird bio (BLUE), Tonix Pharmaceuticals (TNXP), Jin Medical International (ZJYL), Know Labs (KNW), argenx (ARGX), and Panbela Therapeutics (PBLA) witnessed declines ranging from 25.45% to 44.7%. Notably, Know Labs released Q4 earnings the previous day.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 5:31 pm

Aclarion, Inc. (NASDAQ:ACON) shares surged by approximately 53% in pre-market trading due to the grant of a U.S. patent for an MR spectroscopy system to diagnose intervertebral discs related to severe low back pain. Other stocks experienced significant movement in pre-market trading, with various gainers and losers listed, including AEye, Inc. (NASDAQ:LIDR), Applied UV, Inc. (NASDAQ:AUVI), and FedEx Corporation (NYSE:FDX), which saw a pre-market decline after reporting weaker-than-expected earnings and lowering its full-year revenue outlook.

Portfolio Pulse from Avi Kapoor

December 20, 2023 | 1:31 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant movements. Aclarion (ACON) saw a 75.8% increase, while Longeveron (LGVN) rose by 43.07%. Passage Bio (PASG), Dare Bioscience (DARE), Eterna Therapeutics (ERNA), and Kintara Therapeutics (KTRA) also saw upward movements. Conversely, bluebird bio (BLUE), Jin Medical International (ZJYL), argenx (ARGX), Xilio Therapeutics (XLO), Ontrak (OTRK), and Panbela Therapeutics (PBLA) experienced declines, with bluebird bio dropping 45.3%.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 1:07 pm

Compugen Ltd. (CGEN) shares soared by over 200% after Gilead Sciences announced an exclusive licensing agreement for Compugen's pre-clinical immunotherapy program. Other stocks also moved significantly in Tuesday's mid-day session, with various companies experiencing gains due to positive developments such as FDA approvals, business accreditations, and favorable analyst upgrades. Conversely, some stocks fell sharply due to negative events like pricing of public offerings, discontinuation of joint development programs, and unfavorable patent litigation outcomes.

Portfolio Pulse from Avi Kapoor

December 19, 2023 | 6:34 pm

During Tuesday's intraday session, several healthcare stocks experienced significant movements. ProSomnus (OSA) led the gainers with a 68.7% increase, while Motus GI Holdings (MOTS) saw the largest decline among the losers, falling 37.2%. Other notable movers included Panbela Therapeutics (PBLA), Intelligent Bio Solutions (INBS), and bluebird bio (BLUE). Market capitalizations for these companies vary, with Jin Medical International (ZJYL) having the highest at $949.3 million.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 5:32 pm

Panbela Therapeutics Inc (NASDAQ:PBLA) stock surged 62% to $1.64 after announcing FDA approval of eflornithine, a drug they divested to US WorldMeds, for high-risk neuroblastoma patients. The approval marks the first for a polyamine targeted therapy in cancer, with Panbela potentially receiving up to $9.5 million based on milestones. The company's executives are optimistic about the drug's impact on neuroblastoma and other cancers. PBLA's 52-week range is $0.45 to $225.71.

Portfolio Pulse from Henry Khederian

December 19, 2023 | 3:40 pm

U.S. stocks opened higher with the Dow Jones, NASDAQ, and S&P 500 all seeing gains. Materials shares led the market, while financial shares saw a slight decline. Accenture Plc (ACN) reported higher-than-expected Q1 earnings but provided a weaker sales forecast for Q2, expecting revenues to be lower than the consensus. Compugen Ltd. (CGEN), Panbela Therapeutics, Inc. (PBLA), and Jin Medical International Ltd. (ZJYL) saw significant stock price increases. Conversely, Motus GI Holdings, Inc. (MOTS), BYND Cannasoft Enterprises Inc. (BCAN), and ETAO International Co., Ltd. (ETAO) experienced notable declines in their share prices.

Portfolio Pulse from Avi Kapoor

December 19, 2023 | 2:42 pm

Motus GI Holdings, Inc. (MOTS) shares plummeted by 46.5% in pre-market trading after announcing a $5 million public offering. Other stocks experienced significant movement in pre-market trading, with notable gainers including Infobird Co., Ltd. (IFBD), Jin Medical International Ltd. (ZJYL), and SOBR Safe, Inc. (SOBR), among others. Conversely, several companies saw their shares decline, such as ETAO International Co., Ltd. (ETAO), bluebird bio, Inc. (BLUE), and Ebix, Inc. (EBIX), which filed for Chapter 11 bankruptcy.

Portfolio Pulse from Avi Kapoor

December 19, 2023 | 1:09 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.